NEW YORK (GenomeWeb News) Oct. 1 - Aclara Biosciences of Mountain View, Calif., has signed an agreement to provide Rinshoken, the Tokyo Metropolitan Institute of Medical Science, with access to its eTag Assay system, the company said today.
TMIMS researcher Futoshi Shibasaki will use the system to develop multiplexed assays for hypoxia-inducible factors in cells and tissues, which occur in heart attack, stroke, and other cerebrovascular disorders, according to Aclara. Shibasaki's laboratory studies the way gene expression is modulated by hypoxic responsive factors, in an effort to discover diagnostic and therapeutic targets in this area.
The license also includes access to the reagent products, the software, and support for the system.
"We would like to analyze specific proteins for their dependence on HIFs under several experimental conditions that mimic disease situations, Futoshi Shibasaki, director of the Molecular Cell Physiology Laboratory at TMIMS, said in a statement. "Moreover, these types of assays could be valuable for diagnosis and patient stratification in cancer."
This is Aclara's first deal with a Japanese research organization.